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Abstract
Background: Human papillomaviruses (HPV) are the causative agents of cervical cancer in women, which results in
over 250 000 deaths per year. Presently there are two prophylactic vaccines on the market, protecting against the
two most common high-risk HPV types 16 and 18. These vaccines remain very expensive and are not generally
affordable in developing countries where they are needed most. Additionally, there remains a need to treat women
that are already infected with HPV, and who have high-grade lesions or cervical cancer.
Methods: In this paper, we characterize the immunogenicity of a therapeutic vaccine that targets the E7 protein
of the most prevalent high-risk HPV - type 16 – the gene which has previously been shown to be effective in DNA
vaccine trials in mice. The synthetic shuffled HPV-16 E7 (16E7SH) has lost its transforming properties but retains all
naturally-occurring CTL epitopes. This was genetically fused to Zera®, a self-assembly domain of the maize γ-zein
able to induce the accumulation of recombinant proteins into protein bodies (PBs), within the endoplasmic
reticulum in a number of expression systems.
Results: High-level expression of the HPV 16E7SH protein fused to Zera® in plants was achieved, and the protein
bodies could be easily and cost-effectively purified. Immune responses comparable to the 16E7SH DNA vaccine
were demonstrated in the murine model, with the protein vaccine successfully inducing a specific humoral as well
as cell mediated immune response, and mediating tumour regression.
Conclusions: The fusion of 16E7SH to the Zera® peptide was found to enhance the immune responses,
presumably by means of a more efficient antigen presentation via the protein bodies. Interestingly, simply mixing
the free PBs and 16E7SH also enhanced immune responses, indicating an adjuvant activity for the Zera® PBs.
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Background
Cervical cancer is the second most important cause of
cancer-related deaths in women, with half a million diag-
nosed cases and more than 250 000 deaths recorded each
year. This is a direct result of Human papillomavirus
(HPV) infections of the cervical epithelium. The high risk
HPV types 16 and 18 are most prevalent globally in
cervical infections, and are linked to more than 50% and
20% of all cervical cancers, respectively [1]. There are cur-
rently two licensed prophylactic vaccines available: Cervarix
(GlaxoSmithKline) protects against high-risk types HPV-16
and 18 only, while Gardasil (Merck) protects against HPV-
16 and 18, as well as the HPV types 6 and 11 that are the
most common viruses associated with genital warts. These
vaccines have been shown to be very effective in preventing
the onset of cervical cancer, and they are well tolerated [2].
However, they are limited in that they only protect against
the two most prevalent high risk HPV types: there are over
a hundred different HPV types, of which about 40 are
known to infect the genital tract and 12 have been linked to
cervical cancer [3]. These vaccines are also not particularly
suitable for dissemination in developing countries, prima-
rily due to their high cost to individuals or to state vaccine
schemes. Additionally, both of these prophylactic vaccines
only prevent infection, and are not therapeutic for those
* Correspondence: Inga.Hitzeroth@uct.ac.za
†Equal contributors
1Department of Molecular and Cell Biology, University of Cape Town, Private
Bag X3, Cape Town, Rondebosch 7700, South Africa
Full list of author information is available at the end of the article
© 2014 Whitehead et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited.
Whitehead et al. BMC Cancer 2014, 14:367
http://www.biomedcentral.com/1471-2407/14/367
already infected. Therefore, there is still an urgent need
for low-cost and particularly for therapeutic HPV vaccines.
The role of therapeutic vaccines against HPV is to
promote regression of HPV-related lesions. They should
therefore elicit cell-mediated immune responses that are
capable of recognizing HPV-infected and transformed epi-
thelial cells, as opposed to the antibody-based humoral
responses elicited by prophylactic vaccines. Preferentially,
the vaccines should elicit cytotoxic T-lymphocyte (CTL)
responses which act to eradicate infected cells [4].
However, as antibodies can also be involved in the
eradication of infected cells by antibody-dependent cyto-
toxicity (ADCC), an optimal therapeutic vaccine should
induce both a humoral as well as a cellular immune
response [5,6].
The HPV E7 oncoprotein has become a primary focus
as a therapeutic vaccine target, due to its constitutive
and exclusive expression by HPV-infected cells generally,
and in particular by cervical cancers and the prema-
lignant dysplasic cells [7]. E7 is a nuclear protein of 97
amino acids in size, and plays a role in inducing DNA
synthesis in cells partly by means of binding hypopho-
sphorylated retinoblastoma protein (pRB). This disrupts
the interaction between elongation factor 2 and the pRB,
causing the cell to shift to the S phase of the cell cycle
[8]. In cervical cancers and high-grade lesions the HPV
genome is very often integrated into the host genome,
leading to inactivation of the early gene E2 (responsible
for regulating transcription) and subsequent activation
of the oncogenic E7 gene. The E7 protein is then per-
sistently expressed and causes the immortalization of pri-
mary keratinocytes, leading to terminally differentiated,
immortalized clones [9].
In the past, DNA vaccines have clearly demonstrated
they have the ability to induce remarkable CTL respon-
ses [10], and are thus thought to be interesting can-
didates for therapeutic vaccines. Öhlschläger et al. [11]
have shown that immunization of mice with a “shuffled”
HPV-16 E7 gene did not cause cell proliferation, but
induced strong HPV-16 E7-wildtype-specific cellular and
humoral responses without the use of any adjuvant.
Although these findings demonstrated the potential of
therapeutic HPV DNA vaccines, there has been limited
success observed in clinical trials so far [12-14]. More-
over, there are concerns about the potential integration
of the injected DNA into the host genome leading to
long-term complications. Various protein-based HPV
therapeutic vaccines have moved to clinical trials [12,14];
however, there remain concerns over the cost of cell
culture-produced proteins in the context of developing
country needs.
It is thought that plant-produced proteins could provide
an alternative to DNA-based vaccines because they are
cheap, effective [15,16] and, moreover, have been proven
safe for use in humans [17]. A proof of efficacy for a
prophylactic plant-produced papillomavirus L1 protein
vaccine was provided by Kohl et al. [18], who showed
protection in New Zealand White rabbits against warts
caused by cottontail rabbit papillomavirus (CRPV) [18].
HPV 16 L1 protein that assembles into highly immuno-
genic virus-like particles (VLPs) and elicits neutralising
antibodies has been produced successfully at high yield
via transient expression in Nicotiana benthamiana
[19]. A number of groups have also investigated the plant
production of E7-based therapeutic vaccines against HPV-
16, with significant success in murine tumour models
([20,21]. In particular, a plant viral vector/N. benthamiana-
produced E7 mutant (E7GGG, cannot bind Rb) fused to
the Clostridium thermocellum β-1,3-1,4-glucanase (LicKM)
expressed at high yield, elicited E7-specific humoral and
CTL responses in mice, and was both protective against
E7-expressing tumour cell challenge, and therapeutic
against existing tumours [20].
Transient expression systems for recombinant proteins
in whole plants are useful because they allow high-level
production of protein in just a few days, and are easily
scalable [16,22]. Methods for increasing protein yield
include codon optimisation of the genes, and fusion
of signal sequences to target recombinant proteins to
subcellular compartments [18,19]. Signal sequences fused
with the gene of interest can increase protein accu-
mulation and provide protection from degradation by host
cell enzymes.
Additionally, certain sequences may drive assembly
and subsequent sequestration of the polypeptide into
large and highly protected “protein bodies”. One of the
storage proteins of the maize kernel, γ-zein, is naturally
accumulated at high levels into the endoplasmic reticulum
(ER). The functional domains of γ-zein have been well
described [23]. The N-terminal domain, containing eight
PPPVHL repeats and a Pro-X sequence, allows ER
retention and accumulation of fusion proteins in mem-
brane-defined protein bodies, and may also determine
interaction with membranes. The C-terminal cysteine-rich
domain has been hypothesized to have a role in the final
“packing” of the protein bodies due to the formation of
inter- and intra-chain disulfide bonds. The Zera® sequence
generated from the maize γ-zein sequence has been de-
scribed as being sufficient to induce retention of recombin-
ant proteins in protein bodies called StorPro® organelles
(ERA Biotech, Spain), allowing better accumulation of
fusion proteins. In addition, the formation of the large,
stable protein body makes it considerably simpler to
concentrate and purify the protein of interest [24,25].
A further advantage of such protein bodies is that
their co-administration with recombinant vaccines may
have an adjuvant effect and enhance the immune response
as a result of their particulate nature.
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We explored the development of a plant-produced,
potentially therapeutic protein-based vaccine that could
cause regression of HPV lesions in humans infected with
HPV-16, and which would also be affordable in develop-
ing countries. We investigated whether HPV-16E7SH
and Zera® protein bodies can induce tumour regression in
mice. This was tested either by administering 16E7SH-
Zera® fusion proteins or by administering a mixture of Zera®
protein bodies (PBs) and 16E7SH protein to tumourigenic
mice. The proteins were produced in three different ex-
pression systems: HPV-16E7SH protein fused to Zera®
was expressed in plants, HPV-16E7SH was produced in E.
coli and Zera® PBs were produced in insect cells. Immune
responses of the plant-produced protein were compared
to those of the well-characterised E7SH DNA vaccine
in the murine model; tumour regression as well as
cell-mediated and humoral responses were analysed.




The construct into which the 16E7 and 16E7SH genes
were cloned for expression in plants (pTRAc-ZERA-eGFP)
was made as follows: the eGFP gene was amplified from
pEGFP (BD Biosciences) using a forward primer (5’-gatcc
catggacgacgatgataaggtgagcaagggcgaggagctg-3’) which
allowed for inclusion of an enterokinase cleavage site
(DDDDK) at the 5’ terminus of eGFP (italicized sequence),
and the following reverse primer: 5’ cggatccattacttgtac
agctcgtccatgccgag 3’. The amplified product was subcloned
into pUC18ZERA (provided by Era Biotech, Barcelona,
Spain [26] using Nco I and BamH I restriction enzyme
sites such that the Zera® sequence was in frame with the
eGFP fusion to generate pZERA-GFP. This construct was
amplified using primers (5’ actcatgagggtgttgctcgttgc 3’ and
5’ cggaccattacttgtacagct 3’) to enable cloning of the ZERA-
eGFP fusion into the plant expression vector pTRAc (pro-
vided by Rainer Fischer, Fraunhofer Institute, Molecular
Biology and Applied Ecology, Aachen, Germany) [19],
using BspH I and BamH I restriction enzyme sites. The
oncogenic HPV-16 E7 (16E7) gene (Figure 1A) was pro-
vided by J. Schiller (Laboratory of Cellular Oncology,
National Cancer Institute, Bethesda, MD, USA) and
amplified using primers 5'-gatctcatgagtgacgacgatgataa
gatgcatggagatacacctacattg-3'and 5'-agggatccttatggtttctga
gaacagatgg-3'. The product was cloned into the Nco I
and BamH I sites of pTRAc-ZERA-eGFP (replacing
eGFP) forming pTRAc-ZERA-16E7. The shuffled HPV
16E7 (16E7SH) gene (Figure 1A) [11] was amplified
from pTH-16E7SH using the following primers: 5'-
gatcccatggacgacgatgataagatgcacggcgacaccccc-3' and 5'-
aaggatccttatggtttctgagaacagatggggcac-3'. The product
was cloned into the Nco I and BamH I sites of pTRAc-
ZERA-eGFP (replacing eGFP) forming pTRAc-ZERA-
16E7SH. In addition, the modified 16E7SH fragment was
cloned into the Afl III and BamH I sites of the vector
pTRAc, yielding pTRAc-16E7SH.
To construct the recombinant DNA vaccine, ZERA-
16E7SH was amplified from pTRAc-ZERA-16E7SH with
primers 5'-aaaagcttcatgagggtgttgctcgttg-3' and 5'-atgaatt
ctggatccttatggtttctgag-3' and cloned into the pTH vector
Figure 1 Constructs used for making DNA vaccines. (A) The HPV-16 E7 gene was cleaved at the positions corresponding to the pRB binding
site and in between the two Cys-XX-Cys motifs. The cleavage points between amino-acid numbers are shown above the gene. The resulting
fragments were rearranged (“shuffled”) forming the core-element, and an appendix containing the junctions where the cleavage took place was
added to avoid loss of putative CTL epitopes to form 16E7SH. (B) Depiction of the 7 constructs utilised in this study. The core genes and fusions
of genes were cloned into the respective pTH or pTRAc expression vectors.
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[27] using Hind III and EcoR I to yield pTH-ZERA-
16E7SH. The constructs utilised in this study are sum-
marised in Figure 1B. For expression in E. coli, 16E7SH
was cloned into pPROEX™ HT (Life Technologies) and for
expression in insect cells it was cloned into flashBAC
expression vector (Oxford Expression Technologies Ltd.).
Agrobacterium transformation
Three hundred ng of the pTRA constructs were individu-
ally electroporated into A. tumefaciens GV3101 strain with
the pMP90RK helper plasmid as previously described [19].
Electroporated cells were incubated in 1 ml Luria–Bertani
(LB) broth for 2 h then plated on LB medium containing,
50 μg rifampicin ml-1 and 30 μg kanamycin ml-1.
Agroinfiltration and transient expression
Agrobacterium LBA4404 with pBIN-NSs, containing the
TSWV NSs silencing suppressor gene [28], and Agrobac-
terium tumefaciens GV3101::pMP90RK with the pTRAc
constructs were grown in induction medium, prepared for
infiltration and the Agrobacterium suspension was either
injection- (small scale - a few leaves) or vacuum-infiltrated
(large scale - whole plants) into the abaxial air spaces
of 6-8 week old N. benthamiana leaves and left to grow
under 16 h light, 8 h dark at 22°C growth conditions all
previously described until the desired extraction time
ranging from day 1 to day 10 post infiltration [19]. The
constructs were either infiltrated alone or co-infiltrated
with the LBA4404 pBIN-NSs.
Protein extraction
To screen leaf tissue for protein expression, five leaf discs
(5 mm diameter ~ 0.05 g wet plant mass) were ground in
liquid nitrogen, incubated in 200 μl of extraction buffer
(100 mM Tris pH 8, 5% SDS, 5% β-ME, 200 mM NaCl)
with 1× Complete Protease Inhibitor (EDTA-free; Roche)
at 95°C for 20 min. Samples were then incubated at RT for
1 h followed by agitated incubation at 37°C overnight. The
supernatant was clarified by centrifugation for 20 min
(13000 rpm, desktop centrifuge, 4°C) and then detected by
means of western blots.
Protein detection in leaf extracts
Samples were incubated at 85°C for 5 min in loading
buffer, separated on 15% SDS-PAGE, then either stained
with Coomassie blue or transferred onto a nitrocellulose
membrane using the Trans-Blot® SD Semi-Dry Transfer
Cell (Bio-rad) for western blot analysis. E7 proteins were
detected with anti-E7 sera (1:4000) followed by goat anti-
mouse-alkaline-phosphatase conjugate (1:10000; Sigma).
Zera®-containing proteins were detected with polyclonal
anti-Zera® sera (1:5000; ERA biotech) followed by goat
anti-rabbit-alkaline-phosphatase conjugate (1:5000; Sigma).
NBT/NCIP tablets (Roche) were used for final detection.
Proteins were quantified by measuring the density of
the band on a western blot or Coomassie stained bands
in comparison to a known protein concentration stand-
ard, using GeneTools software (SYNGENE) on scanned
images. TSP was determined using the BioRAD assay
according to the manufacturer's instructions.
Large-scale expression and sucrose gradient purification
of protein bodies (PBs)
Large-scale expression and purification was required to
produce vaccine dosages for animal trials. Seven days
post vacuum infiltration, the leaves were cut, weighed,
ground in liquid nitrogen using a pestle and mortar
and resuspended in a ratio of 1:5 (w/v) of buffer PBP3
(100 mM Tris pH 8, 50 mM KCl, 6 mM MgCl2, 10 mM
EDTA, 0.4 M NaCl) made up in 10% sucrose. Samples
were centrifuged at 24 000 rpm for 10 min on ice and
then filtered through a Miracloth™ (Calbiochem). The fil-
trate was loaded onto a sucrose step gradient (19%, 27%,
42%, 56% w/w) and ultracentrifuged at 80 000 g, 4°C for
2 h (Beckman SW32Ti rotor). Protein fractions (IF) of
2 ml were retrieved at the step interface and the pellet
was resuspended in 2 ml PBP3 and analyzed by western
blotting.
Expression of 16E7SH in E. coli
16E7SH protein for animal trials was expressed in E. coli
as detectable levels of its expression in plants were never
achieved. Competent DH5α E. coli cells were transformed
and protein expression was induced as per manufacturer’s
recommendations. The induced cells were pelleted and
lysed (Tris-HCl 50 mM pH 8, NaCl 300 mM,5% gly-
cerol,1 mM DTT). Inclusion bodies containing 16E7SH
were solubilized with solubilization buffer (Tris-HCl
50 mM pH 7.6, NaCl 300 mM, 8 M Urea, 2 mM DTT).
After solubilization, 16E7SH was IMAC-purified twice on
a Ni column, washing bound samples with Triton X-114,
both to purify the protein and to remove endotoxins.
Eluted proteins were further purified twice by size exclu-
sion chromatography (Superdex 200 column, GE Health-
care Life Sciences), the first in the presence of arginine,
and the second with phosphate-buffered saline (PBS). The
resulting protein was analyzed to verify the absence of
LPS contamination with an Endosafe®-PTS™ test system
(Charles River Ltd.).
Insect cell culture and baculovirus production of PBs
Spodoptera frugiperda (Sf9) insect cells (Invitrogen) were
grown in suspension or as monolayers at 28°C in serum-
free SF900 SFM Medium (Gibco). Recombinant baculo-
viruses were produced by co-transfection of Sf9 cells
with flashBAC DNA and transfer vectors pBacPak8
containing the Zera®-encoding sequence, according to
the manufacturer’s recommendations. Recombinant viruses
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were titrated and monolayer Sf9 cultures were infected
with the recombinant baculovirus at a multiplicity of
infection (MOI) of 5.
Zera® protein bodies were isolated from frozen Sf9 cell
biomass previously infected with the selected baculo-
virus. Zera® PBs were recovered as described by Torrent
et al. [26]. PBs washed with LPS-free water were charac-
terized by SDS-PAGE and confocal and scanning electron
microscopy.
Mammalian cell culture
Wildtype HPV-16 E7-expressing 2 F11 cells (C57BL/6
origin, H2b haplotype; [29] were cultured in RPMI 1640
supplemented with heat-inactivated 5% (v/v) foetal calf
serum (FCS, Gibco, Eggenstein, Germany), 2 mM L-glutam-
ine, penicillin (100 U/ml) and streptomycin (100 μg/ml),
G418 (0.8 mg/ml). RMA cells [30] were cultured with the
same medium with the exception of G418.
C3 tumour cells derived from embryonic mouse cells
transfected with the complete HPV-16 genome [31] were
cultured in the same medium as 2 F11 cells, supplemented
with kanamycin (0.1 mg/ml). Splenocytes were cultured in
αMEM (Sigma, Deisenhofen, Germany) supplemented
with 10% FCS, 0.1 mM β-mercaptoethanol, 4 mM glutam-
ine and antibiotics as above for the first 4-5 days after
splenectomy. Subsequently, the splenocytes were cultured
in αMEM+ supplemented with 2.5% supernatant of a
concanavalin-A-induced rat spleen cell culture as a source
of murine IL-2 and 25 mM methyl-α-mannopyranosid
(Sigma, Deisenhofen, Germany).
Immunization of mice
Six-to-eight week old female C57BL/6 mice (owner
bred) were kept under SPF isolation conditions and
standard diet at the animal facilities of the University of
Konstanz, Konstanz, Germany. In the case of DNA injec-
tions, agarose-gel verified plasmids (>95% supercoiled) of
preparations containing less than 0.1 endotoxin units/μg
plasmid DNA as tested earlier by Limulus endotoxin assay
(QIAGEN EndoFree Plasmid Kit). PBs were thoroughly
sonicated on ice. For co-inoculation with PBs and E7 pro-
teins, PBs were mixed with the recombinant homogenized
E7 protein by pipetting on ice directly prior to immuni-
zation (2-4 minutes). For CTL analysis animals were immu-
nized once (100 μg DNA/per animal [50 μg DNA in 50 μl
PBS per musculus tibialis anterior i.m.] or 5 μg ZERA-
16E7SH +/- 100 μl Incomplete Freund’s adjuvant (IFA) or
2.5 μg 16E7SH +/- 2.5 μg Zera® PBs +/- 100 μl IFA per ani-
mal s.c. into the left flank). Ten to 12 days after vaccination
animals were sacrificed and spleens were isolated.
Tumour regression experiments
C57BL/6 mice received 0.5 × 106 HPV-16 E7 expressing
C3 cells [31] in 100 μl of PBS, subcutaneously in the right
shaved flank (needles: 20G 1½” BD Microlance 3). When
small tumours were palpable in all animals (12-15 days
after tumour cell injection), the vaccine was injected i.m.
in both musculus tibialis anterior for the DNA vaccines,
or s.c. into the left flank for protein vaccines, as described
above. Tumour sizes were measured with a caliper. Mice
were sacrificed when the tumour size reached 400 mm2 or
when tumours were bleeding. Tumour sizes of the mice
within a group were calculated as arithmetic means with
standard deviation (SD). All operations on live animals
were performed under Isoflurane anaesthesia.
All animal experiments were performed with approval
by and in accordance with regulatory guidelines and
standards set by the institutional review board at
Regierungspraesidium, Freiburg, Germany.
CTL and humoral responses in vaccinated mice
Data provided were obtained without in vitro restimu-
lation ex vivo, all ELISPOT assays, or after one in vitro
restimulation (51Cr-release assay). In the case of in vitro
restimulation, 2 × 107 splenocytes (pretreated with ACT
lysis buffer [17 mM Tris/HCl, 160 mM NH4Cl, pH 7.2]
to deplete erythrocytes) were co-cultured with 2 × 106
irradiated (100 Gy) HPV-16 E7 wildtype-expressing 2 F11
cells [29] cells in 25 cm2 culture flasks for 5-6 days. Cul-
tures were grown at 37°C and 7.5% CO2 in a humidified
incubator.
IFN-γ/Granzyme B ELISPOT assays
Murine IFN-γ ELISPOT assays were performed ex vivo
as previously described [11]. The Granzyme B ELISPOT
assay was performed similarly to the IFN-γ ELISPOT
assay. For this assay, the anti-mouse Granzyme capture
antibody (100 ng/well, AF1865; R&D Systems, Minneapolis,
USA) and the biotinylated anti-mouse Granzyme detection
antibody (50 ng/well, BAF1865; R&D Systems, Minneapolis,
USA) were used. Splenocytes were seeded in triplicate in
2-fold serial dilutions from 200 000 to 25 000 cells per
well. One of the triplicates was left untreated (negative
control), the second received 200 ng of pokeweed mito-
gen/well (Sigma, Deisenhofen, Germany) in 2 μl of PBS
(positive control), whereas the third received 0.2 μmol
of H2Db-restricted HPV-16 E749-57 peptide in 2 μl
of PBS/well (test sample). Spots of the negative control
(untreated) were subtracted from the spot number in the
corresponding test sample.
51Cr-release assays
The 51Cr-release assays were performed after one in vitro
restimulation of murine spleen cells. One × 104 Na2CrO4-
labelled (0.05 mCi) target cells/well (RMA or E7 wildtype
expressing 2 F11 cells) were incubated together with
decreasing numbers of effector cells in 200 μl per well of a
96-well round bottom plate (Costar, Corning, USA) for
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4 h. Subsequently, 50 μl of supernatant was harvested
from each well and the released radioactivity was mea-
sured in a Microbeta counter (Wallac, Turku, Finland).
Specific lysis was calculated according to the formula:
percent specific lysis = [(cpm of the sample - spontaneous
release)/(total release - spontaneous release)] × 100, where
total release and spontaneous release are measured in
counts per minute (cpm). Spontaneous chromium release
was determined by using 51Cr-labeled target cells without
effector cells, and total chromium release was deter-
mined by adding 2% Triton X-100 to lyse the labelled
target cells.
Humoral antibody titre determination by ELISA
One μg/ml of recombinant HPV-16 E7-wildtype protein
(ProteinX Lab, San Diego, CA, USA, Cat. No. 2003207)
or Zera® protein diluted in PBS was used to coat round-
bottom enzyme-linked immunosorbent assay (ELISA)
plates (Becton Dickinson) by incubating at 4°C over-
night. Wells containing PBS were used as a negative
control. Plates were washed three times with PBS
containing 0.05% Tween 20 and incubated for 1 h at
37°C with 100 μl of milk buffer (5% milk powder and
0.05% Tween 20 in PBS) per well. After the wells were
washed three times with PBS, serum specimens diluted
1:10 in milk buffer, post-immunization [day of splenec-
tomy] were added to two wells in a total volume of 50 μl
per well, and incubated for 1 h at 37°C. Samples were
removed and washed three times with PBS. In order to de-
tect IgGs, HRP-conjugated rabbit anti-mouse IgG (heavy
and light chains) (Zymed, San Francisco, Calif.) diluted
1:3000 were used. After incubation for 1 h at 37°C and
three washes with PBS, substrate (200 μg of tetramethyl-
benzidine per ml in a solution of 0.1 M Na acetate
[pH 6.0] and 0.03% H2O2) was added, the reaction was
stopped with 1 M H2SO4, and the plates were assayed in
an ELISA reader at 450 nm.
Statistical analysis
Differences of means between experimental and control
group were considered statistically significant when p was
less than 0.05 by unpaired Students t-test.
Results
Expression and accumulation of plant-produced
recombinant proteins
In order to determine the protein expression profiles of
the recombinant HPV constructs over time, and the
extent of protection that the PB structures provide for
the recombinant protein against host proteolytic degrad-
ation, protein expression levels in crude leaf extracts were
compared by western blotting.
The constructs (pTRAc-16E7SH, pTRAc-ZERA-16E7SH,
pTRAc-ZERA-16E7 and pTRAc-ZERA-GFP) were
transiently expressed in 8-week old N. benthamiana
plants after syringe co-infiltration of each experimental
recombinant Agrobacterium strain with a strain express-
ing the silencing suppressor NSs. Proteins were extracted
at 3, 5, 7 and 10 dpi. The pTRAc-16E7SH, pTRAc-ZERA-
16E7SH and pTRAc-ZERA-16E7 samples were ana-
lyzed by immunoblotting with the HPV 16E7 antibody
(Figure 2A). Concentrations were estimated by com-
parison with 0.6 μg of bacterially-expressed 16E7SH
protein (≈18 kDa) used as a positive control by means of
densitometry.
ZERA-16E7 protein (expected size of 23 kDa) was not
detected by western blotting in samples harvested at 3
dpi. However, this protein was observed at 5 dpi, and
accumulation increased gradually through 7 dpi to 10 dpi,
with a maximal accumulation of 150 mg/kg measured by
gel densitometry. ZERA-16E7SH protein (expected size of
29 kDa) was seen at 3 dpi and accumulated to much higher
concentrations, starting with a concentration of 400 mg/kg
at 3 dpi and gradually increasing to 1100 mg/kg at 10 dpi.
For further purification studies and preparation of recom-
binant proteins for animal experiments, infiltrated plants
were harvested at 7 dpi, as this was the time at which the
highest protein levels were visualised.
In contrast, 16E7SH protein alone (expected size of
18 kDa) was not detected throughout the same time trials,
indicating the positive effect of the Zera® peptide on the
accumulation of the fusion protein (Figure 2A). A simi-
larly-loaded gel probed with anti-Zera® antibody reacted
with the appropriate Zera®-containing proteins, verifying
the presence of Zera® -specific epitopes on these particular
proteins (data not shown).
Purification of protein bodies for animal trials
Plant leaves were vacuum-infiltrated with pTRAc-ZERA-
16E7SH or pTRAc-ZERA-eGFP, and PBs were purified
at 7 dpi. Extracts from these infiltrated plants were ultra-
centrifuged on a sucrose density step gradient and the
interphase fractions (IF) were aspirated, and tested by
western blotting. Pelleted material at the bottom of the
gradient was also tested by western blotting. Blots were
probed with either anti-16E7 or anti-GFP antibodies to
examine where ZERA-16E7SH and ZERA-eGFP PBs
were positioned on the gradient (Figure 2B). For both
products, the highest levels of recombinant protein were
found in the pellets (P): ZERA-16E7SH could be purified
at 50 mg/kg, and ZERA-eGFP at 200 mg/kg as measured
by densitometry. In both cases, low levels of recom-
binant protein were detected using anti-E7 antibody in
fractions two (IF2) and three (IF3) and an even lower
amount in IF1. Pellets containing the ZERA-16E7SH
PBs were resuspended in endotoxin free PBS and used
in mouse experiments.
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Tumour regression experiments in mice inoculated with
plant-produced ZERA-16E7SH
Tumour regression in mice is associated with stimulation
of cytotoxic T lymphocytes. To determine the therapeutic
potential of plant-produced ZERA-16E7SH protein, the
ability of ZERA-16E7SH protein to cause tumour regres-
sion in tumour-presenting mice was compared to that in
mice inoculated with the DNA vaccine equivalent, pTH-
16E7SH, which was previously shown to cause tumour
regression [11] (Figure 3A). pTH DNA (empty vector)
was used as a negative control. The ZERA-16E7SH plant-
produced protein and the DNA vaccine (pTH-16E7SH)
both caused significant regression of C3 tumours to a
similar extent 14 days after immunization (pTH-16E7SH:
44+/-20 mm2; ZERA-16E7SH: 41+/-10 mm2), when com-
pared to pTH which did not cause any regression.
We further tested whether an adjuvant co-inoculated
with the plant-produced ZERA-16E7SH vaccine affected
the cellular immune response and consequently influenced
tumour size reduction. However, the addition of Freund´s
incomplete adjuvant did not improve the immunogenicity
of ZERA-16E7SH significantly, as further tumour size
reduction was not detected (ZERA-16E7SH + IFA:
48+/-17 mm2; Figure 3A). This suggests that Zera®
protein has an adjuvanting effect by itself, which cannot
be improved under the conditions used in this study.
To determine whether the Zera® protein is immuno-
genic and can induce tumour regression on its own,
mice were inoculated with plant-produced ZERA-eGFP
protein which lacks the immunogenic 16E7 protein: the
results were compared to those of mice inoculated with
the empty DNA vaccine vector control (pTH). No regres-
sion of tumours was observed, with tumours growing at
the same rate as those on mice inoculated with the control
(Figure 3B) indicating that the immune response induced
by the Zera® peptide, if there is any, does not affect
tumour growth.
We subsequently investigated the nature of the cellular
immune response in more detail by carrying out IFN-γ
and Granzyme B ELISPOT assays, as well as chromium
release assays on splenocytes from the vaccinated mice.
The IFN-γ assay (Figure 4A) showed that there was a
significantly enhanced response caused by the plant-
produced protein ZERA-16E7SH in comparison to the
plant-produced protein ZERA-eGFP (p = 0.000428) and
the empty DNA vaccine pTH (p = 0.000182). However,
there was no significant difference measured when these
results were compared to those of inoculation with the
Figure 2 Western blots of crude plant extracts and of purified ZERA-16E7SH and ZERA-eGFP protein. (A) Samples from plants expressing
ZERA-16E7, ZERA-16E7SH and 16E7SH were harvested at 3, 5, 7 and 10 dpi, separated on a polyacrylamide gel and blotted onto nitrocellulose
membrane. Proteins were detected with HPV-16 E7 antibody. 0.6 μg of E. coli- produced purified His-E7 protein was used as a positive (+ve) and
comparative control. SH indicates the use of the shuffled 16E7 gene. + or - indicates the fusion of Zera®. Black arrows indicate the E7 positive
control protein (18 kDa) and the Zera®-fused E7 proteins. (B) Leaves from vacuum-infiltrated N. benthamiana co-infiltrated with pBIN-NSS and
either pTRAc-ZERA-16E7SH or pTRAc-ZERA-eGFP were extracted 5 dpi, ground in liquid nitrogen, homogenized, filtered and separated on sucrose
density gradients. Interphase fractions (IF) were aspirated, pellets (P) were resuspended and run on acrylamide gels, blotted on nitrocellulose
membranes and probed with HPV-16 E7 monoclonal antibody or anti-GFP monoclonal antibody. Black arrows indicate protein bands of
expected sizes.
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pTH-16E7SH DNA vaccine control (mean +/- SEM)
or ZERA-16E7SH co-inoculated with IFA adjuvant
(mean +/- SEM).
Similarly, the chromium release assay (Figure 4B)
showed that the plant-produced ZERA-16E7SH caused
significant specific lysis in comparison to the pTH empty
DNA vaccine control (p = 0.000022) and the plant-pro-
duced ZERA-eGFP protein (p = 0.00157). Results using
pTH-16E7SH or ZERA-16E7SH co-inoculated with IFA
adjuvant again showed similar responses to plant-produced
ZERA-16E7SH with no significant difference between
them, emphasising the lack of immune enhancement
using IFA.
The elevated levels of IFN-γ-secreting cells in spleno-
cytes isolated from mice inoculated with ZERA-16E7SH
as well as concomitant increased cell lysis in chromium-
release assays, suggest that activated cytotoxic T-lympho-
cytes are responsible for the control of the tumour growth.
Since Granzyme B is an important marker of activated
cytotoxic T-lymphocytes and a prerequisite for the lysing
of tumour cells, Granzyme B secretion assays were carried
out to confirm this (Figure 4C). HPV-16 E7 wild-type
expressing cells were used as targets. We demonstrated a
significant response generated by the plant-produced
ZERA-16E7SH in comparison to the ZERA-eGFP protein
(p = 0.000609). Again, the addition of the IFA adjuvant
failed to improve the immune response significantly.
However, when the IFA was added as an adjuvant to
ovalbumin (OVA) as a control, it generated a significant
response (p = 0.000377), indicating that the IFA was viable
as an adjuvant in other circumstances (Figure 4C).
Determination of the role of Zera® protein in the immune
response
Results from the above experiments demonstrate that
the vaccine candidate ZERA-16E7SH is able to induce a
strong cellular immune response which is able to medi-
ate control of tumour growth. Moreover, due to the fact
that IFA is normally able to enhance the cellular response
of an irrelevant protein but lacks this ability when used in
combination with ZERA-16E7SH, the experiments sug-
gest that the Zera® peptide may play a role in adjuvanting
the vaccine candidate which could not be further enhan-
ced by IFA.
In order to distinguish between the role of Zera® in
this immunogenic response and that of IFA, it was com-
pared to the regression of tumours in tumourigenic mice
(i) inoculated with Zera® PBs or 16E7SH proteins and (ii)
co-inoculated with individual Zera® PBs and 16E7SH
proteins. As we were not able to express 16E7SH alone
Figure 3 Tumour regression in mice inoculated with different vaccines. Mice were inoculated with 0.5 × 106 C3 tumour cells to induce
tumours and subsequently injected with vaccine (5 μg protein or 100 μg DNA in 100 μl) in two sites per animal when the tumours were clearly
palpable. Surface tumour size was measured over time. Because some tumours became bloody in some animals of the control group (empty
vectors), the experiment was terminated at day 14. Data gives the mean ± SEM of the indicated group (n = 10). A) Animal groups injected with
100 μg pTH DNA, or 100 μg pTH-16E7SH DNA, or 50 μg plant-produced ZERA-16E7SH protein or ZERA-16E7SH protein plus adjuvant (IFA). B) Animal
groups injected with control DNA (pTH) or plant-produced ZERA-eGFP protein.
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in plants to any reasonable concentration for inoculation
doses, we expressed this recombinant protein in E. coli
as this method resulted in the production of adequate
amounts of 16E7SH easily. In addition, the Zera® PBs
used in these experiments were produced in insect cells
as their expression using this method is high (+/- 40 mg/L),
and recovery is very efficient. Zera® PBs from insect
cells and tobacco plants are also very similar in that they
are round, range in size from 0.5 to 1 μm, membrane-
surrounded and do not undergo post-translational modifi-
cation [32].
This experiment was repeated twice and the results
presented in Figure 5 show that only mice co-inoculated
with the 16E7SH and Zera® proteins showed a significant
tumour regression. 16E7SH protein did not cause any
significant reduction in tumour size. Similarly, Zera® pro-
tein alone did not cause tumour regression, indicating that
Zera® has no anti-tumour properties on its own. Addition-
ally, as observed previously, the inoculation with IFA did
not modify the tumour regression efficacy of any of the
inoculations tested.
Inoculation of mice with the cognate DNA vaccines
(pTH-16E7SH and pTH-ZERA-16E7SH) also confirmed
their ability to cause tumour regression, with pTH-
ZERA-16E7SH showing a significantly stronger control
of tumour growth. The corresponding inoculation with
pTH-ZERA also did not have any effect in decreasing
tumour growth (Figure 5). With these experiments we
could clearly demonstrate that Zera® has an immu-
nostimulatory role which cannot be substituted by an
adjuvant.
Splenocytes from these mice were also subjected to
IFN-γ and Granzyme B ELISPOT assays, as well as chro-
mium release assays to determine the nature of the im-
mune response in the mice.
IFN-γ secretion of cytotoxic T lymphocytes
IFN-γ levels of splenocytes isolated from mice inoculated
with DNA in 2 biological repeat experiments showed
elevated amounts in mice inoculated with pTH-16E7SH
and pTH-ZERA-16E7SH DNA, compared to those inocu-
lated with pTH-ZERA or pTH DNA only (Figure 6A).
The Zera®-containing construct led to a stronger induc-
tion of IFN-γ secretion: this was statistically significant
(p: 0.04) in Exp. I and not (p: 0.2) in Exp. II. IFN- γ assays
on sera from mice inoculated with 16E7SH protein alone
Figure 4 IFN-γ response, CTL activity and Granzyme B ELISPOT assays on mouse splenocytes. Four mice per group were injected either
with 5 μg protein or with 100 μg DNA per animal, respectively. (A) Ex vivo IFN-γ ELISPOT responses. Given are the means of IFN-γ secreting cells/
104 splenocytes ± SEM. ZERA-16E7SH compared to ZERA-eGFP (p < 0.001) and to pTH (p < 0.001). (B) Splenocytes were tested by 51Cr-release
assays after one round of in vitro re-stimulation for lysis of E7-wildtype expressing 2 F11 target cells. Data is given as mean ± SEM. ZERA-16E7SH
compared to ZERA-eGFP (p < 0.001) and to pTH (p < 0.001). (C) Ex vivo Granzyme B ELISPOT responses. Four mice per group were immunized
with 5 μg protein injected per animal. Given are the means of Granzyme B-secreting cells/104 splenocytes ± SEM. ZERA-16E7SH compared to
ZERA-eGFP (p < 0.001) and to OVA (p < 0.001).
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showed only very moderate responses which were not
significantly enhanced by IFA. This outcome corresponds
with data shown earlier (Figure 5). Importantly, the IFA
lot used in this study enhanced the immunogenicity of a
protein-based vaccine in another context (data not shown),
proving that its lack of boosting the immune response was
not due to malfunction of the adjuvant.
Interestingly, a comparison of the mice inoculated
with 16E7SH protein with those co-inoculated with
16E7SH protein and Zera® protein (PBs) shows a clear
enhancement of the immunogenicity by Zera® PBs, with
both experiments showing statistical significance (p: 0.004
in Exp. I and 0.0003 in Exp. II). When IFA adjuvant was
added to the inoculation dose consisting of 16E7SH and
16E7SH and Zera® PBs, the responses of animals were
similar, again showing that Zera® PBs enhanced the
immune response.
Granzyme B ELISPOT assays
The Granzyme B ELISPOT assays performed on samples
from mice inoculated with DNA showed similar trends
(Figure 6B). Comparison of samples pTH-16E7SH and
pTH-ZERA-16E7SH indicate an elevated immune response
compared to pTH-ZERA or pTH alone, although these
responses were not statistically significant for either of the
biologically repeated experiments (p: 0.06 in Exp. I, p: 0.06
in Exp. II). The Granyzme B ELISPOT assays performed
on samples from mice inoculated with protein showed
a significant difference when comparing the effect of
16E7SH protein alone and the effect of 16E7SH pro-
tein and Zera® PBs (p: 0.0001 in Exp. I, and 0.03 in
Exp. II). The effect of adding IFA to 16E7SH and to
16E7SH+ Zera® PBs did not show a significant increase in
Granzyme B-secreting cells, confirming that Zera® has an
adjuvanting effect.
Chromium release assay
Chromium release assays carried out on splenocytes
from vaccinated mice showed a trend indicating an en-
hanced response (lysis of target cells) (Figure 6C). This
included the comparison of the response between mice
inoculated with pTH-16E7SH and those inoculated with
pTH-ZERA-16E7SH (p: 0.0849), which was similar to
the observations between cognate samples measured in
IFN-γ and Granzyme B secretion assays (Figure 6A and B).
A trend of increased cell lysis was observed when compar-
ing the response of mice inoculated with 16E7SH protein to
those co-inoculated with 16E7SH protein and Zera® PBs, al-
though the measurements were not statistically significant
(p: 0.0513 in Exp. I and p: 0.1051 in Exp. II) (Figure 6C).
A similar trend was observed in the IFA-supplemented
groups (16E7SH protein + IFA and 16E7SH protein +
Zera® PBs + IFA), where again IFA did not enhance im-
mune responses.
Humoral antibody response
We further wanted to determine if Zera® generates an im-
proved humoral immune response after DNA and protein
vaccination. We therefore investigated the presence of
anti- Zera® and anti-16E7 IgG in serum samples from
vaccinated mice using an ELISA. The comparison of the
pTH-16E7SH- and pTH-ZERA-16E7SH-treated groups
showed the induction of significantly increased levels of
anti-E7 IgG by the ZERA-construct (p: ≤0.0022) (Figure 7).
As expected, anti-ZERA IgG was only detected in the
pTH-ZERA and pTH-ZERA-16E7SH-treated group. The
16E7SH protein induced an anti-E7 IgG response that was
significantly enhanced when co-inoculated with Zera® PBs
(16E7SH + Zera® PBs) (p: ≤0.0025) (Figure 7). When mice
were inoculated with Zera® PBs alone, they were able to
induce high levels of anti- Zera® IgGs as expected, but
there was no enhancement detected in mice inoculated
with Zera® PBs + IFA (Figure 7). Interestingly, again IFA
did not cause an enhanced anti-E7 IgG response when
comparing samples from mice co-inoculated with 16E7SH
protein + Zera® PBs with or without IFA.
Figure 5 Tumour regression in mice inoculated with Zera®
separately. Mice received 0.5 × 106 C3 tumour cells s.c. and when
the tumours were clearly palpable they were immunized with
100 μg DNA vaccine or 2.5 μg 16E7SH +/- 2.5 μg Zera® PBs +/-
100 μl IFA per animal and surface tumour size was measured.
Experiments were repeated (Exp. I and Exp. II) and both results are
shown. The experiment was terminated at day 39 due to the size of
tumours in the control groups (empty vectors). Data gives the
mean ± SEM. of the indicated group at day 39 but in the second exp:
on day 43 (n = 10). pTH-ZERA-16E7SH DNA compared to pTH-16E7SH
(Exp. I - p < 0.05, Exp. II p = 0.2). 16E7SH protein compared to 16E7SH
protein plus Zera® PBs (Exp. I - p < 0.005, Exp. II p < 0.0005).
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Discussion
There is a need for therapeutic HPV vaccines that elimin-
ate existing lesions and malignant tumours by inducing
cell-mediated immune responses against HPV-infected
cells. Presently, various strategies such as DNA based,
peptide- and protein based and live-vector based vaccines
are utilized [12]. DNA vaccines have emerged as poten-
tially useful HPV therapeutic vaccines, but there is limited
success after clinical trials of DNA vaccines so far and in
the actual commercialization of the product. Moreover,
the fear of DNA integration into the host genome and
subsequent genomic instability remains. Therapeutic pro-
tein vaccines, on the other hand, are generally considered
safe. One drawback of protein vaccines is that they are
often not very immunogenic, and often need either to be
fused to other immunogenic proteins, or have adjuvant
added, in order to increase their immunogenicity. Produc-
tion of protein vaccines can also be very costly when it is
done in mammalian cells and the concern of contamin-
ation by other human or human-infecting viruses remains.
Plant-produced proteins could provide an alternative as
they can be produced economically and have been shown
to be safe for use in humans [16].
In this study we investigated if the plant-produced
shuffled HPV16 E7 protein fused to Zera® is a suitable
candidate as a therapeutic vaccine for HPV-16 infections
and HPV-related tumours. An artificial shuffled HPV-16
E7 gene (16E7SH) was selected as it has previously been
shown to cause regression of tumours in mice when
tested as a DNA vaccine. 16E7SH was fused to Zera®, a
novel signal sequence which promotes the formation of
protein bodies during expression of fusion proteins. We
wanted to investigate the role of Zera® in increasing
16E7SH production in plants, and also its role in enhan-
cing the immunogenicity of the plant-produced protein.
Lastly, the possibility that free Zera® could act as an
Figure 6 Ex vivo IFN-γ, CTL activity and Granzyme B ELISPOT responses in mice inoculated with Zera® separately. Two groups of four
mice were immunized with 100 μg DNA vaccine, or 2.5 μg 16E7SH +/- 2.5 μg Zera® PBs +/- 100 μl IFA per animal for each assay. (A) Ex vivo IFN-γ
ELISPOT responses. Given are the means of IFN-γ secreting cells/104 splenocytes ± SEM. (B) Ex vivo Granzyme B ELISPOT responses. Four mice per
group were immunized with 5 μg protein injected per animal. Given are the means of Granzyme B-secreting cells / 104 splenocytes ± SEM.
16E7SH protein compared to 16E7SH protein plus Zera® PBs (Exp. I - p = 0.0001, Exp. II p < 0.05). (C) The splenocytes were tested by 51Cr-release
assays after one round of in vitro restimulation for lysis of syngeneic E7-wildtype expressing 2 F11 target cells. Data gives the mean ± SEM of the
indicated group (n = 4). One representative of the two experiments is shown.
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adjuvant was explored by mixing Zera® PBs with the puri-
fied 16E7SH protein.
For safety reasons the use of wildtype HPV-16 E7 for
vaccination is not feasible in humans. Approaches like
the introduction of point mutations into the E7WT gene,
however, lead to an unwanted loss of naturally occurring
epitopes that is potentially associated with a decrease in
vaccine efficacy. We used a rearranged (“shuffled”) E7
sequence which lacks transforming properties [11].
Ultimately this non-transforming HPV-16E7SH supplies
all potential naturally-occurring T cell epitopes, covering
the broad range of MHC restriction. Consequently, prior
knowledge of the patient’s HLA-haplotype is not required
which is especially important in the outbred human
population. In addition, a more potent immune response
may be induced, involving all occurring HLA-restriction
elements in the vaccine.
We tested whether 3 different recombinant HPV16
E7-derived proteins could be produced in plants. The
expression in plants of recombinant protein from con-
structs encoding 16E7SH alone, 16E7SH fused to Zera®,
and Zera® fused to wildtype HPV-16E7, was assessed
by comparing expression at 3, 5, 7 and 10 dpi. ZERA-
16E7SH and ZERA-16E7 proteins were successfully ex-
pressed in plants as 29 and 24 kDa fusion proteins,
respectively. However, the expression of 16E7SH alone
was not detected, indicating that fusion with Zera® en-
hanced accumulation levels of the protein in plants. The
incorporation of a silencing suppressor increased ZERA-
16E7SH accumulation by 6-fold, indicating that post-
transcriptional gene silencing (PTGS) plays a role in the
expression of the proteins.
This increase with addition of a silencing suppressor is
lower than other reported increases, such as the 30-fold
increase measured using with GFP expression [33]. How-
ever, the accumulation of ZERA-eGFP reached ±25 g/kg
in our experiments (data not shown), which was more
than 70-fold higher than the GFP expression reported by
Voinnet et al. [33].
The Zera®-HPV proteins were expressed at levels ran-
ging from 0.1 - 6 g/kg. ZERA-16E7SH levels were the
highest, varying from 1 - 6 g/kg. This was 2-fold higher
than that obtained by Massa et al. [20], who attained
levels of 0.4 g/kg for E7 fusion protein production in
N. benthamiana. In contrast, expression of the 16E7SH
protein alone was too low to quantitate, due either to a
very poor level of expression, and/or to degradation
during extraction.
The time trial expression profiles showed stable pro-
tein accumulation up to 12 dpi in samples infiltrated
with ZERA-eGFP and for the ZERA-16E7 constructs.
This is much longer than seen in previous studies where
the expression of the proteins peaked at 60-70 h, even
with the addition of a silencing suppressor [33]. Protein
degradation in the cytoplasm is one of the reasons
behind this decreasing protein concentration, which is
alleviated by the sequestration of the proteins into PBs.
As the Zera® fusion protein is translated, it is directly
sequestered into ER-derived and membrane-delimited
protein bodies. It is thought that this encapsulation
Figure 7 Humoral response of mice inoculated with Zera® separately. Four mice per group were immunized with 100 μg DNA vaccine or
50 μg protein and blood was taken post-immunization (day of splenectomy). Direct ELISA was performed against both Zera® and 16E7 protein
using anti-Zera and anti-16E7 IgGs. Data gives the mean ± SEM of duplicates of the indicated group (n = 4). One representative of the two experiments
is shown. pTH-ZERA-16E7SH DNA compared to pTH-16E7SH (p < 0.005), 16E7SH protein compared to 16E7SH protein plus Zera® PBs (p < 0.005).
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protects the fusion protein from proteolytic degra-
dation. At the same time, the PBs serve as a very
useful means for purification of the proteins, as they
are dense organelles which can be easily purified on den-
sity gradients [26].
The ability of the plant-produced ZERA-16E7SH PBs
to cause tumour regression was shown to be significant
and similar to that of the DNA vaccine equivalent. Fur-
ther co-inoculation of ZERA-16E7SH PBs with adjuvant,
however, did not significantly enhance tumour regres-
sion suggesting that Zera® has an adjuvanting effect
by itself. Inoculation of tumourigenic mice with plant-
produced ZERA-eGFP lacking 16E7SH also did not
result in tumour regression suggesting that Zera is not im-
munogenic. Despite the fact that it has been shown that
eGFP is minimally immunogenic in C57/BL6 mice [34],
the lack of tumour regression observed when mice were
inoculated with ZERA-eGFP further supports the evi-
dence that the 16E7SH is the immunogen causing tumour
regression and that Zera® does not contribute to this.
The pTH-ZERA-16E7SH construct appeared able to
induce higher immune responses than the Zera®-free
counterpart (pTH-16E7SH); however, the data were not
in all cases statistically significant. In general, the DNA-
based vaccines were more efficacious than the protein-
based vaccines in the context of control of tumour
growth (Figure 5), which probably reflects in part the
fact that DNA vaccines induce more Th1 than Th2 re-
sponses after intramuscular injections. The pTH-16E7SH
construct did, however, also induce a moderate IgG
response, as measured by ELISA (Figure 7). Additionally,
IFN-γ levels of splenocytes isolated from mice inoculated
with pTH-ZERA-E7SH were elevated compared to mice
inoculated with pTH-16E7SH (Figure 6). This trend was
also observed in Granzyme B ELISPOT assays as well as
in chromium release assays.
One way to enhance potencies of DNA vaccines is to
increase antigen expression in professional antigen pre-
senting cells, such as dendritic cells. As ZERA-16E7SH
is expressed well in plants, and 16E7SH is not, it can be
speculated that ZERA-16E7SH is also expressed to much
higher levels from a DNA vaccine in mammalian cells
than 16E7SH alone, and that this would in turn enhance
CTL response induced by this DNA vaccine [12]. In fact,
the increase in protein accumulation due to fusion with
Zera® and production of PBs has been observed in mam-
malian cells as well as other organisms [32]. It can be
speculated that PBs are also formed in the mammalian
cells that are inoculated with the DNA vaccine. It re-
mains unclear how such heterologous organelles, which
typically are retained in the ER, could in turn enhance
the immune response as we observed in this study.
In our study we showed that Zera®-PBs were clearly able
to stimulate humoral and cellular immune responses
either as ZERA-16E7SH fusion protein or as Zera® PBs
co-inoculated with 16E7SH proteins. Normally, subunit
protein vaccines are not very efficient in the induction of
the cellular immune responses; thus, this finding could be
of great interest in the context of protein-based thera-
peutic vaccines. It is well known that professional antigen
presenting cells like DCs and macrophages favour the up-
take of particles with repeating sequence motifs. The adju-
vanting effect of Zera® could also be due to its particulate
nature. Interestingly, in our hands IFA was in no case able
to enhance immune responses significantly in the pres-
ence of Zera®, which was wholly unexpected. The same
IFA lot used in the present study induced an enhancement
of the antibody response after immunization with other
antigens (highly purified recombinant OVA (data not
shown)). In addition, despite the fact that IFA is com-
monly used to enhance Th2-directed responses, we obser-
ved in the OVA immunizations an effect on the Th1
response.
Conclusions
In summary, we were able to transiently express a ZERA-
16E7SH fusion protein to very high levels in plants, in
contrast to the free 16E7SH protein. We were able to
demonstrate that fusion with the Zera® peptide signifi-
cantly enhances expression of a HPV 16E7SH protein in
plants. The Zera® fusion protein and Zera® PBs mixed with
the 16E7SH protein alone enhanced cellular and humoral
immune responses to 16E7SH. These responses could not
be further enhanced by the addition of a common adju-
vant, and we speculate that Zera® has adjuvanting capabil-
ities and is able to enhance CTL and antibody responses
in both DNA and protein vaccines. We feel we have
demonstrated proof of efficacy in a mouse tumour model
of a novel HPV therapeutic vaccine candidate, which
should be easy and cheap to produce and purify. For
further development of this therapeutic vaccine, a DNA
prime followed by protein boost might be ideal in order to
achieve further enhancements in immunogenicity.
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